Limitation of myocardial infarct size by atenolol, nadolol and propranolol in dogs.
The importance of cardioselectivity and membrane depressant activity in the ability of beta-adrenergic antagonists to limit myocardial infarct size was assessed in the dog. Infarction was produced by a 60 min occlusion of the left circumflex coronary artery followed by reperfusion into a critical stenosis. Infarct size was significantly reduced by atenolol, nadolol and propranolol. Thus, limitations of infarct size by beta-adrenergic antagonists occur with agents which possess or lack cardiac selectivity or membrane depressant activity.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D001262:Atenolol / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004285:Dogs; D005260:Female; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D008566:Membranes / Q000187:drug effects; D009203:Myocardial Infarction / Q000188:drug therapy*; D009248:Nadolol; D011412:Propanolamines / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D009248:Nadolol; D001262:Atenolol; D011433:Propranolol